<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; without</title>
	<atom:link href="http://www.tapanray.in/tag/without/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Emerging markets and a robust oncology portfolio expected to be the future growth engine of the global pharmaceutical industry&#8230; but not without associated pricing pressures.</title>
		<link>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures</link>
		<comments>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 01:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[associated]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[engine]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[portfolio]]></category>
		<category><![CDATA[pressures]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[without]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=760</guid>
		<description><![CDATA[When the growth rate of the developed markets of the global pharmaceutical industry started slowing down along with the declining R&#38;D productivity, the emerging markets were identified as the new ‘El-Dorado’ by the global players. At the same time, new &#8230; <a href="http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is the revised Mashelkar Committee Report a ‘please all’ report, without taking any chance to &#8216;rock the boat&#8217;?</title>
		<link>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat</link>
		<comments>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/#comments</comments>
		<pubDate>Mon, 15 Jun 2009 01:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[boat]]></category>
		<category><![CDATA[chance]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[incremental innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[please]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[rock]]></category>
		<category><![CDATA[Taking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[without]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=860</guid>
		<description><![CDATA[After repeated request and persuasion by the Government of India (GoI) in general and the Department of Industrial Policy and Promotion (DIPP) in particular ‘The Mashelkar Committee’re-submitted its reports to the GoI under the following terms of references: Terms of &#8230; <a href="http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
